SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Teva Pharmaceutical Industries Limited and Alcobra Announce Phase II Trial of Novel, Non-Stimulant MG01CI for ADHD Meets Primary Endpoint